---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-112383"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:23:32.865114+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protara TARA-002 STARBORN-1: 100% clinical success in evaluable patients

## Summary
- 8/8 evaluable patients (100%) achieved clinical success at eight-week assessment.
- 80% (8/10) of patients that completed treatment achieved clinical success.
- 5/6 macrocystic patients had complete response; mixed cystic patient also complete response.
- No serious adverse events; common AEs were swelling and fatigue; one discontinuation due to Grade 2 fatigue.
- Two LMs patients reached 32-week post-treatment and remain disease-free.

## SEC filing metadata
- accession: 0001213900-25-112383
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390025112383/0001213900-25-112383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390025112383/ea0266384-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-112383
- JSON: https://secwatch.observer/filing/0001213900-25-112383.json
- Plain text: https://secwatch.observer/filing/0001213900-25-112383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.